GlassScriptPhysician profile
Krista Robbins
NPI 1447710181
$1,802.46
in general payments reported to CMS, 2019-2025
23 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $335 · 2024: $372 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.92 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $351.04 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $258.10 | 2023-2025 | Ubrelvy |
| Lilly USA, LLC | $212.72 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $156.32 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.76 | 2025 | Caplyta |
| Pfizer INC. | $98.13 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $68.74 | 2024-2025 | Breztri |
| Exact Sciences Corporation | $62.96 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $60.01 | 2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $59.52 | 2024-2025 | |
| Corium, LLC | $56.66 | 2023-2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.23 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $45.94 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $40.73 | 2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.36 | 2023-2025 | Xifaxan, Trulance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $25.24 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $21.37 | 2025 | Gemtesa |
| Collegium Pharmaceutical, INC. | $20.16 | 2025 | Jornay Pm |
| Abbott Laboratories | $16.18 | 2024 | Freestyle Libre 3 |
| Cranial Technologies, INC | $15.67 | 2024 | Doc Band |
| Radius Health, INC. | $14.77 | 2025 | Tymlos |
| Merck Sharp & Dohme LLC | $14.39 | 2025 | Gardasil 9, Enflonsia, Capvaxive |
| Novartis Pharmaceuticals Corporation | $13.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.